Triple-negative breast cancer subtype (TNBC) comprised 37% of the cohort, while HR+/HER2, HR+/HER2+, and HR-/HER2+ accounting for 22.2%, 14.8% and 7.4%, respectively. This evidence concerns the gene ERBB2 and breast carcinoma.